"We are not all things to all people, but we now have a much stronger product line and we will have a much heavier investment in cattle health,” says Tim Bettington, director of livestock marketing for BIVI.
With the purchase of Fort Dodge, BIVI adds the Cydectin family of dewormers to its portfolio. As such it now lays claim to 47% of the pour-on wormer market and 6% of the injectable wormer market.
In the mastitis area, BIVI picks up Today and Tomorrow mastitis tubes. Those additions catapult BIVI to 27% market share in lactation treatments and 38% in dry cow treatments.
BIVI also picked up a number of vaccines in both modified live (Pyramid) and killed lines (Triangle), pushing its market share to 25% in the vaccine market, second only to Pfizer Animal Health.
Initially, dairy producers will see little change with these acquired products. But by adding these products and by hiring Fort Dodge scientists and technical veterinarians, the new team will be a research-driven to provide innovative technologies as new diseases emerge.
BIVI typically invests 12% of its annual revenue in research and development. In 2008, Boehringer Ingelheim posted net sales of $17 billion from human, livestock, equine and companion pet sales.
For more information on BIVI, click here